dichlororibofuranosylbenzimidazole has been researched along with Malignant Melanoma in 2 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourcier, C | 1 |
| Griseri, P | 1 |
| Grépin, R | 1 |
| Bertolotto, C | 1 |
| Mazure, N | 1 |
| Pagès, G | 1 |
| Blaydes, JP | 1 |
| Craig, AL | 1 |
| Wallace, M | 1 |
| Ball, HM | 1 |
| Traynor, NJ | 1 |
| Gibbs, NK | 1 |
| Hupp, TR | 1 |
2 other studies available for dichlororibofuranosylbenzimidazole and Malignant Melanoma
| Article | Year |
|---|---|
Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.
Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Benzenesulfonates; Cel | 2011 |
Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways.
Topics: Amino Acid Sequence; Cyclin-Dependent Kinases; Dichlororibofuranosylbenzimidazole; DNA Damage; Enzym | 2000 |